In this retrospective analysis, researchers used real-world data to investigate sex-associated differences in CAR T-cell therapy-related toxicity.

Rutgers University researchers find that certain aging immune T cells can blunt cell expansion and may help explain why many ...

CAR T-cell therapy is a treatment that uses a patient’s own T cells, genetically reprograms them in a lab to recognize ...

Researchers have reported two major immunology advances: Weill Cornell Medicine scientists found that activated T cells secrete DNA-filled vesicles that can enhance immune responses against tumors, ...

After a surprise rejection at the beginning of 2026, the FDA has agreed to reconsider a T-cell therapy based on the same ...

I f your doctor has recommended chimeric antigen receptor (CAR) T-cell immunotherapy for large B-cell lymphoma (LBCL), you’ve likely already tried several standard treatments, and the cancer did not ...

A detailed analysis of T-cell redirecting therapies in oncology, comparing the mechanisms of bispecific antibodies and CAR T cells.

Soficabtagene geleucel (WU-CART-007) received FDA Breakthrough Therapy Designation for treating relapsed or refractory T-cell leukemia and lymphoma. The CRISPR-engineered treatment achieved a 91% ...

Organ transplantation remains the cornerstone treatment for end-stage organ failure. While conventional broad-spectrum immunosuppression effectively controls acute rejection, it fails to address ...